In December 2012, Hongri Pharmaceutical’s trademark Xuebijing was recognized as a well-known trademark by the Trademark Office of the State Administration for Industry and Commerce. In December 2012, Hongri Pharmaceutical won the Tianjin Patent Excellence Award

(Patent name: A quality testing method for traditional Chinese medicine Xuebijing Injection) In February 2013, Hongri Pharmaceutical successfully passed the GMP certification and obtained the pharmaceutical GMP certificate. In March 2013, Hongri Pharmaceutical won the Tianjin Science and Technology Progress Award. Second Prize (Project Name: Key Technologies and Applications for the Secondary Development of Famous and High-Quality Chinese Patent Drugs) In March 2013, Hongri Pharmaceutical won the second prize of the Tianjin Science and Technology Progress Award (Project Name: Innovative Drugs with the Transformation and Industrialization of Scientific and Technological Achievements as the Core R&D engineering project) In May 2013, it won the honor of "Top 100 Capital Brand Premiums of China's Listed Companies in 2013". In August 2013, Hongri Pharmaceutical ranked seventh among the top 20 most competitive pharmaceutical listed companies in China in the fifth session

Won the top ten of the top 20 most valuable companies listed on China's GEM in 2013

Won the "Best Board of Directors of China's Small and Medium-sized Board and GEM Listed Companies in 2013"

Founder Yao Xiaoqing won the title of "2013 Most Respected Chairman of China's Listed Companies"